Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439732 | 0.93 | OPRK1 (0.53) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| SCHEMBL13439733 | 0.93 | OPRK1 (0.53) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| SCHEMBL10607349 | 0.88 | OPRK1 (0.61) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| Hydrochloric Acid SCHEMBL10607357 | 0.86 | OPRK1 (0.60) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| SCHEMBL13439728 | 0.86 | ROCK1 (0.58) | OPRK1ROCK1ROCK2CCR2MAOB | |
| SCHEMBL13439723 | 0.86 | ROCK1 (0.58) | OPRK1ROCK1ROCK2CCR2MAOB | |
| SCHEMBL13439718 | 0.86 | SMN1; SMN2 (0.67) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| SCHEMBL11742319 | 0.83 | OPRK1 (0.65) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| SCHEMBL13462821 | 0.83 | OPRK1 (0.65) | OPRK1SMN1; SMN2GAAHRH3ROCK1 | |
| SCHEMBL4855546 | 0.82 | HRH3 (0.74) | OPRK1SMN1; SMN2GAAHRH3ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | OPRK1 416/4885SMN1; SMN2 3807/4885GAA 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.